Enhanced Tumor Site Accumulation and Therapeutic Efficacy of Extracellular Matrix‐Drug Conjugates Targeting Tumor Cells
Small · 2024
DOI: 10.1002/smll.202402040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Zhoujiang Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Advanced Study, Chengdu University, Chengdu, Sichuan, 610106, P. R China. Hauptthemen laut MEDLINE: Doxorubicin, Extracellular Matrix, Nanoparticles. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Natural Science Foundation of Sichuan Province, Central Government for Guiding Local Science and Technology Development of Sichuan Province, Open Research Fund of State Key Laboratory of Southwestern Chinese Medicine Resources.
Abstract (Originalsprache)
The extracellular matrix (ECM) engages in regulatory interactions with cell surface receptors through its constituent proteins and polysaccharides. Therefore, nano‐sized extracellular matrix conjugated with doxorubicin (DOX) is utilized to produce extracellular matrix‐drug conjugates (ECM‐DOX) tailored for targeted delivery to cancer cells. The ECM‐DOX nanoparticles exhibit rod‐like morphology, boasting a commendable drug loading capacity of 4.58%, coupled with acid‐sensitive drug release characteristics. Notably, ECM‐DOX nanoparticles enhance the uptake by tumor cells and possess the ability to penetrate endothelial cells and infiltrate tumor multicellular spheroids. Mechanistic insights reveal that the internalization of ECM‐DOX nanoparticle is facilitated through clathrin‐mediated endocytosis and macropinocytosis, intricately involving hyaluronic acid receptors and integrins. Pharmacokinetic assessments unveil a prolonged blood half‐life of ECM‐DOX nanoparticles at 3.65 h, a substantial improvement over the 1.09 h observed for free DOX. A sustained accumulation effect of ECM‐DOX nanoparticles at tumor sites, with drug levels in tumor tissues surpassing those of free DOX by several‐fold. The profound therapeutic impact of ECM‐DOX nanoparticles is evident in their notable inhibition of tumor growth, extension of median survival time in animals, and significant reduction in DOX‐induced cardiotoxicity. The ECM platform emerges as a promising carrier for avant‐garde nanomedicines in the realm of cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute for Advanced Study, Chengdu University, Chengdu, Sichuan, 610106, P. R China.
- School of Pharmacy, Zunyi Medical University, Zunyi, Guizhou, 563099, P. R China.
- School of Pharmacy, Chengdu University, Chengdu, Sichuan, 610106, P. R. China.
- Department of Orthopaedics, Shanghai Key Laboratory for Prevention and Treatment of Bone and Joint Diseases, Shanghai Institute of Traumatology and Orthopaedics, Ruijin Hospital, Shanghai Jiao Tong University School of…
ORCID-Profile: Zhoujiang Chen, Wenguo Cui
Förderung
- Natural Science Foundation of Sichuan Province
- Central Government for Guiding Local Science and Technology Development of Sichuan Province
- Open Research Fund of State Key Laboratory of Southwestern Chinese Medicine Resources
- Chengdu University
Zitieren
APA
Chen, Z., Long, L., Wang, J., Jiang, M., Li, W., Cui, W., & Zou, L. (2024). Enhanced Tumor Site Accumulation and Therapeutic Efficacy of Extracellular Matrix‐Drug Conjugates Targeting Tumor Cells. Small. https://doi.org/10.1002/smll.202402040
Vancouver
Chen Z, Long L, Wang J, Jiang M, Li W, Cui W, et al. Enhanced Tumor Site Accumulation and Therapeutic Efficacy of Extracellular Matrix‐Drug Conjugates Targeting Tumor Cells. Small. 2024. doi:10.1002/smll.202402040
BibTeX
@article{Chen2024,
author = {Chen, Zhoujiang and Long, Lianlin and Wang, Ji and Jiang, Mingli and Li, Wei and Cui, Wenguo and Zou, Liang},
title = {Enhanced Tumor Site Accumulation and Therapeutic Efficacy of Extracellular Matrix‐Drug Conjugates Targeting Tumor Cells},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202402040}
}
EUVIMED